PHONE: 517.536.8210
FAX: 517.536.8205


TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Posts by TPPS

Entrepreneurial plunge pays off for former Pfizer employees

Dan and Samantha Ross had just built a 4,000-square-foot log cabin for themselves in Jackson County when their employer, the drug giant Pfizer Inc., announced it was closing its sprawling campus in Ann Arbor. They could have taken another position with Pfizer in Connecticut, but they had no intention of leaving. “I knew what I wasn’t going to do, and that was move,” said Dan Ross. So the couple took an entrepreneurial plunge. Together, they founded TransPharm Preclinical Solutions LLC, a fast-growing biotech company based in Napoleon Township, a small community in southern Jackson County. Read...

Read More

Handling deadly diseases, Michigan company earns $12 million in first 10 years

NAPOLEON TWP., MI – The hit item is usually the freezer – which is kept at minus 80 degrees – when Daniel Ross takes school groups through TransPharm Preclinical Solutions. Most people in the community haven’t heard of his business and don’t know what it does, said Ross, president and CEO. He shows students around to bring awareness to the work that’s happening in their small town. “We don’t have to be in a big city,” said Marci Peek, contract and protocol specialist. “In little Napoleon, Michigan, we have clients all over the world.” TransPharm has 10 full-time employees and 101 clients in 13 countries. Located in rural Napoleon Township, the life sciences company reached its 10-year anniversary on Jan. 2.  Read...

Read More

Fall 2017 Newsletter

A Note from the President The year is coming to a close and 2018 is right around the corner. It’s hard to believe, but January will mark TransPharm’s 10-year anniversary. Our company started with just three employees, but ten years later we have quadrupled in size. The total revenue our first year was $147k; now we do over $2 million annually. Time flies when you’re having fun! To celebrate our landmark anniversary and as a thank you to our clients, we are offering 10% off all studies booked by December 21st. See below for more details. Also, we’d like to remind you that TransPharm will be closed starting Monday, December 25th and will reopen on Tuesday, January 2nd. The last day for animal deliveries is December 18th, with studies ending on the 22nd. Studies for early January (and any that you wish to be 10% off!) should be booked by December 21st. We will be checking email periodically, and this is the best way to reach us during our break. We wish you and yours a joyous holiday season and a happy new year. Daniel Ross President & CEO 10% Off ALL Studies! Celebrate our 10-year anniversary with 10% off! All studies booked* by 12/21/2017 are eligible for the discount. Contact Marci for a quote today! *Signed quotes and a purchase order must be received by end of business on Thursday, December 21, 2017. In the Lab TransPharm has added a new animal model of induced chronic osteomyelitis (bone infection). Osteomyelitis results in pain, loss of mobility, and significant morbidity. Current treatment requires prolonged antibiotic therapy and surgical debridement of sequestra (dead bone). Due to poor drug penetration into the bone and an increase in antibiotic-resistant bacteria, there is an urgent need for novel therapeutics. Our model serves as a screening tool to identify which antimicrobials are most clinically efficacious. Animals are challenged via injection into the cancellous bone marrow through the anterior surface of the proximal tibia (see photo). The infection is allowed to incubate for up to 4 weeks before the tibia is harvested for CFU enumeration. The induced chronic osteomyelitis model is currently available for S. aureus and S. epidermidis infections in Sprague-Dawley rats. Additional validations are available...

Read More

Summer 2017 Newsletter

A Note from the President It’s been a busy summer here at TransPharm and we are on track for another record year. Our team has been hard at work and we’re excited to share an inside look at what we do. The video below gives a great overview of our role in preclinical infectious disease research. It highlights our niche focus – animal models of bacteria, viruses, parasites, and fungi – which has cultivated an expertise that sets us apart from other contract research organizations. As specialists, we can serve as professional consultants to help you design a study that meets both your needs and your budget. You’ll also get a glimpse of our state-of-the-art laboratory and animal care facilities, as well as hear about how we manage such quick turn-around times for our clients. We have a passion for knowledge and scientific discovery and feel honored to play even a small part in the drug development process. It is our goal that our work will contribute to new and potentially life-saving therapies. We hope you enjoy the video and don’t forget to subscribe to our YouTube channel to see future content. Daniel Ross President & CEO In the Lab We are searching for TransPharm’s Next Top Model! Our team has been focused on validating new murine models of infectious disease, including Haemophilus influenzae pneumonia, Staphylococcus epidermidis peritonitis, Streptococcus pyogenes soft tissue infection, and Acinetobacter baumannii deep wound infection. Upcoming validations will follow-up on the 2017 summer internship program projects as well as validating new comparators against H. influenzae, P. acnes, and VRE. Contact us today to request a validation or no-obligation quote. Speaking of our internship program, it was featured in a recent edition of the Brooklyn Exponent. All four of our 2017 interns – Paige, Brandon, Jen, and Trevor – did a fantastic job in the lab. We are looking forward to meeting next year’s applicants! Santiago R. Lopez, Ph.D. Chief Scientific Officer Publications Many of our clients have published their research and acknowledged TransPharm’s role in their work. Check out a few of the manuscripts and poster presentations based on studies we’ve completed, including a P. acnes skin infection, a pulmonary model of Pseudomonas aeruginosa, a C. difficile gastrointestinal infection, as well as models of candidiasis, aspergillosis, and cecal ligation and puncture...

Read More

Spring 2017 Newsletter

A Note from the President Spring has finally sprung in Michigan and things are looking especially sunny here at TransPharm. We celebrated our best first quarter in history, and the first intern of our summer internship program is finishing up validation of an A. baumanii pulmonary infection model. Lunches are spent at the picnic table on our patio, and everyone is enjoying a newly constructed trail which weaves through the woods to a pond on the property. Warmer weather isn’t the only change we’ve noticed. Today’s economy relies on technology more than ever before, and a growing number of customers want to interact with businesses in a way that is most convenient for them. For this reason, our team has decided to pursue a different marketing strategy than in years past. In lieu of attending the American Society for Microbiology conference in June, we will be using our resources to expand our digital presence. Keep your eyes open for original media content highlighting our niche services, and be sure follow us on Facebook for the latest and greatest. Daniel Ross President & CEO The trail on our property leads through the woods to a pond nestled among the willow trees. Wild geraniums (above) and lily of the valley grow along the trail. In the Lab Many bacteria live in our gut and on our skin, usually without causing problems. However, serious infections can occur when these bacteria become resistant to antibiotics. Vancomycin-resistant enterococci, or VRE, are one such threat. Although healthy people are unlikely to become infected with VRE, those who are hospitalized or have weakened immune systems are especially at risk. TransPharm has a well-established murine model of VRE colonization in the gastrointestinal tract, one of the most common sites for infection. Antibiotic pre-treatment provides consistent results, with fecal shedding peaking on Days 3-5 and observed through Day 15. Our screening studies are flexible enough to accommodate studies with prophylactic and/or daily dosing. We also have personnel and areas of our facility dedicated specifically to VRE work. Contact us today for a quote! Santiago R. Lopez, Ph.D. Chief Scientific Officer Marci Peek promoted to Senior Protocol Specialist We are excited to announce that Marci Peek has been promoted to Senior...

Read More